NCT04412304

Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 166 (actual)
• Sponsor: Karolinska Institutet · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Conditions

• Covid-19
• Thromboembolic Events
• Bleeding

Interventions

Type	Name	Description
DRUG	Dose of Tinzaparin or Dalteparin	The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.

Timeline

• Start date: 2020-03-06
• Primary completion: 2020-04-30
• Completion: 2020-05-28
• First posted: 2020-06-02
• Last updated: 2020-06-22

Locations

1 site across 1 country: Sweden